Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine
The Geneva Foundation · with Brooke Army Medical Center, Uniformed Services University of the Health Sciences · NCT06402318
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–89 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 100
- US sites recruiting
- 1
- Study start
- December 27, 2023
- Record last updated
- December 10, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The primary objective of this effort will be to optimize and operationalize innovative passive surveillance systems and in parallel, the effort will identify, evaluate, and transition groundbreaking new technologies in diagnostics for operationalization.
To meet the objective and execute the deliverables for this program of effort, the A\&M Breathalyzer PROTECT Kiosk will be tested, modified and validated at Brooke Army Medical Center (BAMC). The collaborative efforts between the PI, Dr. Michael Morris at BAMC and Co-Investigator Dr. Tony Yuan at USU- Center for Biotechnology (4D Bio3) will assess the passive detection technology and provide a capability survey of use-case scenarios for different operational settings.
Goals
- Optimization and operationalize the A\&M Breathalyzer PROTECT Kiosk, portable mass spectrometer (MS) Detector for Deployment in Military Operational Medicine Environments. The Breathalyzer will be deployed to BAMC to test its detection capabilities of COVID-19 among symptomatic and asymptomatic COVID-19 carrier vs. those not infected compared to gold standard RT-PCR.
- Evaluate the passive sensing, breath capture system, built within the A\&M Breathalyzer PROTECT Kiosk. The conversion of the active breath capture system, currently requires a straw that the subject breaths into, where then a series of sensors built in the Breathalyzer would automatically sample the exhaled breath within proximity for recent COVID-19 exposure. This task would conclude with a set of sensors and sensor inputs that would be analyzed by the Atomic AI platform built in the device. Field testing at BAMC is planned to determine the level of detection and discrimination for sensor combinations to SARS-CoV2 components and biomarkers detected. This testing would update the Atomic AI algorithm, within the device, to understand the accuracy of positive detection and the resulting sensitivities.
Being studied: A&M Breathalyzer PROTECT Kiosk
Conditions: COVID-19; SARS CoV 2 Virus; COVID-19 Pneumonia; COVID-19 Respiratory Infection; COVID-19 Acute Respiratory Distress Syndrome
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Asymptomatic and symptomatic individuals 18 years and older
- Receiving standard COVID-19, Flu and/or RSV screening and testing at BAMC
- Do not have to be diagnosed with SARS-CoV-19 (COVID-19) but only be screened
- Ability to understand consent
Exclusion Criteria
- Any individual under age of 18
- Anyone unable to comply (or be assisted) with study procedures
- Anyone not able to provide temperature thermal scan, and/or perform exhaled breath for approximately 8 seconds
Recruiting US locations
Brooke Army Medical Center
Fort Sam Houston, TX 78234
Site contact: Katherine Walker-Rodriguez, MSN · 2103783057 · katherine.c.walker-rodriguez.ctr@health.mil
Study contacts (from the official record)
- Tony Yuan, PhD · 214-292-0508 · tony.yuan@usuhs.edu
- Katherine Walker-Rodriguez · 2103783057 · katherine.c.walker-rodriguez.ctr@health.mil
Similar studies in Texas
All healthy volunteers studies in Texas →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study of LY4355756 in Healthy Participants
Eli Lilly and Company
- Location
- Dallas, TX
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
AstraZeneca
- Location
- San Antonio, TX + 1 other US site
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight
Eli Lilly and Company
- Location
- San Antonio, TX
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Radiprodil in Participants With Hepatic Impairment
GRIN Therapeutics, Inc.
- Location
- DeSoto, TX + 1 other US site
- Eligibility basics
- Ages 18–75